Minocycline protects SH-SY5Y cells from 6-hydroxydopamine by inhibiting both caspase-dependent and -independent

Bernardino Ossola1, Tiina A Lantto, Katja A Puttonen

  • 1Division of Pharmacology and Toxicology, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland. bernardino.ossola@helsinki.fi

Insights

Minocycline protects neurons by inhibiting apoptosis and also affects caspase-independent cell death pathways. This neuroprotective antibiotic may accelerate the clearance of aberrant proteins, offering novel therapeutic insights.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Cell Biology

Background:

  • Minocycline is known for anti-inflammatory and anti-apoptotic effects.
  • Its impact on caspase-independent programmed cell death (PCD) pathways remains unexplored.

Purpose of the Study:

  • To investigate the effects of minocycline on caspase-independent PCD pathways.
  • To elucidate the mechanisms of minocycline's neuroprotection against 6-hydroxydopamine (6-OHDA) in SH-SY5Y cells.

Main Methods:

  • Utilized SH-SY5Y human dopaminergic cells challenged with 6-OHDA.
  • Assessed apoptosis (caspase-3 activity, DNA fragmentation, chromatin condensation) and caspase-independent PCD.
  • Monitored protein synthesis and degradation.

Main Results:

  • Minocycline demonstrated neuroprotection, inhibiting 6-OHDA-induced apoptosis.
  • 6-OHDA activated caspase-independent PCD (paraptosis) requiring protein synthesis.
  • Minocycline's protective effect was only partially explained by apoptosis inhibition.
  • Minocycline reduced cellular protein content while increasing protein synthesis, suggesting enhanced protein degradation.

Conclusions:

  • Minocycline inhibits both conventional apoptosis and caspase-independent PCD pathways.
  • The drug's neuroprotective action involves mechanisms beyond apoptosis inhibition.
  • Minocycline may enhance the clearance of aberrant proteins, indicating potential for treating proteinopathies.

Related Concept Videos

Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...